| 1 | Cancer | 2.3% | |
| 2 | Patients | 2.3% | |
| 3 | Medicina | 2.3% | |
| 4 | Results | 2.3% | |
| 5 | ASCO | 2.3% | |
| 6 | Phase | 2.3% | |
| 7 | Clinical | 1.15% | |
| 8 | Mexico | 1.15% | |
| 9 | Clinically | 1.15% | |
| 10 | Neoadjuvant | 1.15% | |
| 11 | Study | 1.15% | |
| 12 | Rapid | 1.15% | |
| 13 | Borja | 1.15% | |
| 14 | Reviewed | 1.15% | |
| 15 | Hospital | 1.15% | |
| 16 | Toluca | 1.15% | |
| 17 | Sugar | 1.15% | |
| 18 | Natural | 1.15% | |
| 19 | Policiacas | 1.15% | |
| 20 | Advanced | 1.15% | |
| 21 | New | 1.15% | |
| 22 | Molecular | 1.15% | |
| 23 | Effusion-Synovitis | 1.15% | |
| 24 | Osteoarthritis | 1.15% | |
| 25 | Czechia | 1.15% | |
| 26 | Wegovy | 1.15% | |
| 27 | Aprueban | 1.15% | |
| 28 | Have | 1.15% | |
| 29 | Cisplatin-Ineligible | 1.15% | |
| 30 | (BT8009) | 1.15% | |
| 31 | San | 1.15% | |
| 32 | UAEMex | 1.15% | |
| 33 | Nectin-4?targeting | 1.15% | |
| 34 | Noticias | 1.15% | |
| 35 | Pevedotin | 1.15% | |
| 36 | Duravelo-1 | 1.15% | |
| 37 | Metastatic | 1.15% | |
| 38 | Edomex | 1.15% | |
| 39 | Balance | 1.15% | |
| 40 | DISCERN | 1.15% | |
| 41 | Inauguran | 1.15% | |
| 42 | Accurate | 1.15% | |
| 43 | Deficient | 1.15% | |
| 44 | Men | 1.15% | |
| 45 | Effect | 1.15% | |
| 46 | Niraparib | 1.15% | |
| 47 | IARC-coordinated | 1.15% | |
| 48 | Zelenectide | 1.15% | |
| 49 | Locales | 1.15% | |
| 50 | Not | 1.15% | |
|
는 분류, 데이터 기준으로 의 기사에서 의 고유명사 데이터를 통해 생성되었습니다.
|
|||